A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of HL217 Eye Drop in Healthy Male Subjects

NCT03650608 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Subject

Interventions

DRUG: Cohort 1: HL217 Ophathalmic Solution QD
DRUG: Cohort 2: HL217 Ophathalmic Solution BID
DRUG: Cohort 3: HL217 Ophthalmic Solution QID
DRUG: Placebo Ophthalmic solution

Sponsor

Hanlim Pharm. Co., Ltd.